ArticleFrontiers in cardiovascular medicine2026
Mortality trends and disparities in older U.S. adults with atrial fibrillation and COPD: a 1999-2020 CDC WONDER analysis with forecast to 2030.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is prevalent in elderly individuals with comorbidities, particularly those with chronic obstructive pulmonary disease (COPD), where their coexistence increases mortality risk. This study examines mortality trends and disparities among U.S. adults aged 65 and older affected by both AF and COPD from 1999 to 2020. Methods: We analyzed CDC WONDER mortality records for deaths with both AF and COPD listed on the death certificate. Age-adjusted mortality rates (AAMRs) were assessed, and temporal trends were evaluated using annual and average annual percent changes (APC/AAPC) via Joinpoint regression. An ARIMA model was used to project mortality rates through 2030. Results: A total of 399,413 deaths were recorded. The AAMR increased from 27.39 in 1999 to 65.29 in 2020, reflecting an AAPC of 4.21 (95% CI: 3.75-4.68). Men had a higher AAMR (57.01) than women (34.96). Non-Hispanic White individuals had an AAMR 2.8 times higher than Hispanics. Non-metropolitan areas had a higher AAMR than metropolitan areas. The leading causes of death were COPD, ischemic heart disease, and cancer, with the most common place of death shifting from medical facilities to home by 2020. Projections suggest the AAMR will reach 92.62 by 2030, with the highest increase observed in individuals aged ≥85. Conclusion: Mortality involving coexisting AF and COPD in older adults has increased over the past two decades, with disparities across sex, race, and geography. Projections indicate continued mortality increases, emphasizing the need for targeted interventions in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.